Interobserver Variability of Ki-67 Measurement in Breast Cancer

다국어 초록 (Multilingual Abstract)

Background: As measurement of Ki-67 proliferation index is an important part of breast cancer diagnostics, we conducted a multicenter study to examine the degree of concordance in Ki-67 counting and to find factors that lead to its variability. Methods: Thirty observers from thirty different institutions reviewed Ki-67–stained slides of 20 different breast cancers on whole sections and tissue microarray (TMA) by online system. Ten of the 20 breast cancers had hot spots of Ki-67 expression. Each observer scored Ki-67 in two different ways: direct counting (average vs. hot spot method) and categorical estimation. Intraclass correlation coefficient (ICC) of Ki-67 index was calculated for comparative analysis. Results: For direct counting, ICC of TMA was slightly higher than that of whole sections using average method (0.895 vs 0.858). The ICC of tumors with hot spots was lower than that of tumors without (0.736 vs 0.874). In tumors with hot spots, observers took an additional counting from the hot spot; the ICC of whole sections using hot spot method was still lower than that of TMA (0.737 vs 0.895). In categorical estimation, Ki-67 index showed a wide distribution in some cases. Nevertheless, in tumors with hot spots, the range of distribution in Ki-67 categories was decreased with hot spot method and in TMA platform. Conclusions: Interobserver variability of Ki-67 index for direct counting and categorical estimation was relatively high. Tumors with hot spots showed greater interobserver variability as opposed to those without, and restricting the measurement area yielded lower interobserver variability.

참고문헌 (Reference)

1 Laurinavicius A, "methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue" 16 : R35-, 2014

2 Wong SC, "The contribution of bifunctional SkipDewax pretreatment solution, rabbit monoclonal antibodies, and polymer detection systems in immunohistochemistry" 131 : 1047-1055, 2007

3 Goldhirsch A, "Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011" 22 : 1736-1747, 2011

4 Carey LA, "Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study" 295 : 2492-2502, 2006

5 Colozza M, "Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?" 16 : 1723-1739, 2005

6 Fasanella S, "Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies" (6Suppl 1) : S7-, 2011

7 Dowsett M, "Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer" 99 : 167-170, 2007

8 Viale G, "Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole" 26 : 5569-5575, 2008

9 Goldhirsch A, "Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013" 24 : 2206-2223, 2013

10 Perou CM, "Molecular portraits of human breast tumours" 406 : 747-752, 2000

11 Cheang MC, "Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer" 101 : 736-750, 2009

12 Yerushalmi R, "Ki67 in breast cancer: prognostic and predictive potential" 11 : 174-183, 2010

13 Penault-Llorca F, "Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer" 27 : 2809-2815, 2009

14 Luporsi E, "Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review" 132 : 895-915, 2012

15 Ekholm M, "Immunohistochemical assessment of Ki67 with antibodies SP6 and MIB1 in primary breast cancer: a comparison of prognostic value and reproducibility" 65 : 252-260, 2014

16 Nielsen TO, "Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma" 10 : 5367-5374, 2004

17 SØrlie T, "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications" 98 : 10869-10874, 2001

18 Mohammed ZM, "Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer" 106 : 383-388, 2012

19 Zabaglo L, "Comparative validation of the SP6 antibody to Ki67 in breast cancer" 63 : 800-804, 2010

20 Bruno S, "Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60cells" 25 : 31-40, 1992

21 Polyak K, "Breast cancer: origins and evolution" 117 : 3155-3163, 2007

22 Dowsett M, "Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group" 103 : 1656-1664, 2011

23 Polley MY, "An international Ki67 reproducibility study" 105 : 1897-1906, 2013